JPRN-jRCTs021210077招募中未知
Exploratory study to evaluate the efficacy and safety of tocilizumab for Takayasu's arteritis based on classification by type of autoantibody - Exploratory study to evaluate the efficacy and safety of tocilizumab for Takayasu's arteritis based on classification by type of autoantibody
Ishii Tomonori0 个研究点目标入组 20 人开始时间: 2022年3月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who meet all of the following conditions (1) to (5)
- •1) Patients over 20 years old (at the time of consent)
- •2) Patients diagnosed with Takayasu's arteritis according to any of the following criteria at the time of registration. It does not matter whether tocilizumab is used or not.
- •1.2017 Ministry of Health, Labor and Welfare Takayasu's Arteritis Diagnostic Criteria
- •2.American Rheumatology Society (ACR) ,Takayasu's Arteritis Diagnostic Criteria (1990)
- •3) Patients with no inflammatory findings of Takayasu's arteritis at the time of registration
- •4) Patients whose steroid dose at the time of registration can be reduced to 20 mg / day or less in terms of prednisolone.
- •5) Patients who can confirm the history of recurrence on the medical record under the administration of steroids with prednisolone equivalent of 7.5 mg / day or more. It is assumed that any of the following is present as a necessary symptom or finding as a recurrence symptom.
- •Headache, dizziness, systemic symptoms (fever, malaise, weight loss, joint symptoms, muscle symptoms, etc.), vascular lesions and associated symptoms, CRP persistent positive
排除标准
- •Check the following at the time of registration and exclude patients who fall under any of the following. Regarding the confirmation of the criteria corresponding to (4) to (9), If there is a clinical test result conducted within 4 weeks (28 days) before registration (Day 1), even if it is a test performed before obtaining consent, it is possible to judge from the result.
- •1) Patients who received new or increased doses of immunosuppressive agents other than steroids within 4 weeks (28 days) before registration
- •2) Patients who received biologics other than tocilizumab and rituximab (anti-TNF-alpha preparation, abatacept, anti-IL-6 receptor preparation, etc.) within 3 months (12 weeks) before registration.
- •3) Patients who received rituximab within 6 months (24 weeks) before enrollment
- •4) Patients with severe renal impairment (nephrotic syndrome, serum creatinine of 2.5 mg / dL or higher)
- •5) Patients with severe liver dysfunction (child classification B or higher)
- •6) Patients with severe cardiac dysfunction (ischemic heart disease, heart failure) or findings requiring treatment on electrocardiogram / echocardiography
- •7) Patients with drug-resistant hypertension
- •8) Patients with malignant tumor or history of malignant tumor (excluding cases without recurrence for 5 years or more)
- •9) HBsAg positive, HIV positive, HCV positive patients
- •10) Patients with serious infections
- •11) Pregnant or lactating women and women wishing to become pregnant during the study period
- •12) Patients who have participated in clinical trials such as clinical trials using unapproved drugs or new drugs or post-marketing clinical trials within the past 6 months
- •13) In addition, patients who are judged to be inappropriate for inclusion in this study by the investigator / responsible physician (hereinafter referred to as the investigator, etc.)
研究者
相似试验
进行中（未招募）
1 期
Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical ventilatioAcquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.MedDRA version: 20.0Level: PTClassification code 10077255Term: Intensive care unit acquired weaknessSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002329-56-ESSociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)200
招募中
2 期
Exploratory Study to Evaluate the Efficacy and Safety of Baricitinib in Interstitial Pneumonia Associated with Anti-MDA5 Antibody-Positive DermatomyositisInterstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositisJPRN-jRCTs031220641Fujio Keishi5
尚未招募
不适用
The exploratory study for the efficacy and the safety of Rikkunshito on symptoms of indigestion in the patients with Functional HeartburFunctional HeartburnJPRN-UMIN000029668ippon Medical School Graduate School of Medicine20
已完成
不适用
The exploratory study for the efficacy and the safety of Hangeshashinto on symptoms of heartburn /belch in the patients with gastroesophageal reflux disease (GERD)GERDJPRN-UMIN000021251Osaka Medical College80
已完成
不适用
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.Abdominal pain and abdominal fullness feeling in the patients with fecal incontinenceJPRN-UMIN000030252Medical Corporation Seiaikai, Gion Usshita Hospital50